Data curation to accelerate drug development.

Qureight accelerates clinical trial development at key decision points through data curation and AI-powered decision making. We work with pharmaceutical companies, contract research organisations and hospitals to curate data and help the best drugs get approved: so they can be given to patients who need them the most. We are currently focused on lung and heart disease.

Our AI-powered technology stack enables collaborative analysis for imaging, clinical data and biomarkers


Uncovering powerful insights from complex trial data

Our platform allows our partners to run AI based data analytics on complex trial data including images, clinical data and biomarkers

Our proprietary technology includes AI based image algorithms for CT scans, AI assisted workflows and central image read cloud based technology


A connected view of lung and heart diseases

Our AI models are backed up and built through real world data accessed through our partner healthcare institutions

All data from clinical trials is structured and available to our pharmaceutical clients

Collaborations with partnering hospitals worldwide for real world data curation and analysis


Purpose-built technology created by world-leading experts in healthcare data

Zero-footprint medical imaging viewing with ability for annotation and AI model runs

Fast, efficient and AI-guided central read image workflows for clinical trials

Ability to generate synthetic study arms

Access to our Key Opinion Leaders network

AI-powered quantitative imaging analysis of CT scans including quantification of lung volumes, airways, pulmonary vessels and fibrosis

Trusted by

“Push the boundaries of science”

The collaboration with Qureight supports AstraZeneca’s aim to harness data and technology to push the boundaries of science and deliver life-changing medicines to patients. Qureight’s AI technology allows us to investigate outcomes in multiple respiratory diseases, create new endpoints and improve patient selection for clinical trials in diseases such as Idiopathic Pulmonary Fibrosis.

Professor Maria Belvisi
SVP Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D

“This insight will prove invaluable”

Vicore’s work with Qureight has highlighted information from our data that we otherwise wouldn’t have had access to. Following this analysis, we now know which patients are most likely to improve with C21, and how. This insight will prove invaluable as we continue our work to provide a much-needed new IPF treatment.

Dr. Rohit Batta
Chief Medical Officer

“Effectively and efficiently setting up all the necessary steps”

The Qureight team helped smooth the transition of data transfer by effectively and efficiently setting up all the necessary steps prior to the transfer (creating a storing data location, providing access, providing input on data organization, etc) and collectively working with Clario to resolve any questions in a timely manner.

Katie Gilliam
Project Manager, Imaging

Our current disease focus areas

Interstitial lung diseases

Interstitial lung diseases (ILDs) are a group of diseases which cause scarring and damage to the lung tissue itself. They can be difficult to diagnose and monitor and clinical trial development pathways can be complex. They encompass over 200 individual diseases including Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis and Hypersensitivity Pneumonitis. Drug treatment can vary from steroids to immunosuppression to antifibrotics.  Some patients may have associated pulmonary hypertension and others may need a lung transplant.

Pulmonary hypertension

Pulmonary Hypertension (PH) is an umbrella term for a group of conditions which cause an increased pressure in the heart/lung vascular circuit. This pressure increase can be cause by a range of diseases including autoimmune diseases, problems with the lungs or the heart itself, blood clots or can be of unknown cause. Monitoring it can be hard needing invasive procedures to pass tubes into the blood vessels to directly measure the pressures. A new range of drugs to treat these diseases are being developed many different biopharma companies.

Lung cancer

Lung cancer is one of the most common and fatal types of cancer. It can be associated with smoking, genetics or industrial exposures. The cancer can be primary which starts in the lung or secondary which has spread to the lungs from other parts of the body. Treatments include surgery, radiotherapy, chemotherapy and targeted immunotherapy. Some of the newer medications can cause damage to the lung tissue surrounding the cancer as a side effect of the treatment.